Skip to main content
. 2020 Jun 5;9(6):1762. doi: 10.3390/jcm9061762

Table 2.

Adverse events.

Any Grade Grade 3–4
All adverse events > 15%, n (%)
 Anemia 27 (75.0) 0 (0.0)
 Hypoalbuminemia 27 (75.0) 0 (0.0)
 Platelet count decreased 21 (58.3) 0 (0.0)
 Neutrophil count decreased 15 (41.7) 1 (2.8)
 Paronychia 15 (41.7) 0 (0.0)
 Decreased appetite 15 (41.7) 4 (11.1)
 Diarrhea 15 (41.7) 1 (2.8)
 White blood cell decreased 14 (38.9) 1 (2.8)
 Aspartate aminotransferase increased 14 (38.9) 2 (5.6)
 Fatigue 13 (36.1) 3 (8.3)
 Dermatitis acneiform 13 (36.1) 0 (0.0)
 Alanine aminotransferase increased 11 (30.6) 0 (0.0)
 Alkaline phosphatase increased 11 (30.6) 2 (5.6)
 Creatinine increased 11 (30.6) 0 (0.0)
 Pruritus 8 (22.2) 0 (0.0)
 Mucositis oral 8 (22.2) 0 (0.0)
Grade 3–4 adverse events, n (%)
 Pneumonitis 4 (11.1) 2 (5.6)
 Left ventricular systolic dysfunction 1 (2.8) 1 (2.8)
 Electrocardiogram QT prolongation 1 (2.8) 1 (2.8)
 Delirium 1 (2.8) 1 (2.8)
 Hallucination 1 (2.8) 1 (2.8)
 Dyspnea 1 (2.8) 1 (2.8)
 Dehydration 1 (2.8) 1 (2.8)
 Lung infection 2 (5.6) 1 (2.8)
 Sinusitis 1 (2.8) 1 (2.8)